The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.

Taxanes, including docetaxel (DOCE), are severely neurotoxic, causing disabling peripheral neuropathy. Co-treatment with neuroprotective agents has been proposed to prevent or reverse this. Besides its hemopoietic effects, erythropoietin (EPO) has neuroprotective and neurotrophic properties and when...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Cervellini, I, Bello, E, Frapolli, R, Porretta-Serapiglia, C, Oggioni, N, Canta, A, Lombardi, R, Camozzi, F, Roglio, I, Melcangi, R, D'incalci, M, Lauria, G, Ghezzi, P, Cavaletti, G, Bianchi, R
Định dạng: Journal article
Ngôn ngữ:English
Được phát hành: 2010
_version_ 1826291487000756224
author Cervellini, I
Bello, E
Frapolli, R
Porretta-Serapiglia, C
Oggioni, N
Canta, A
Lombardi, R
Camozzi, F
Roglio, I
Melcangi, R
D'incalci, M
Lauria, G
Ghezzi, P
Cavaletti, G
Bianchi, R
author_facet Cervellini, I
Bello, E
Frapolli, R
Porretta-Serapiglia, C
Oggioni, N
Canta, A
Lombardi, R
Camozzi, F
Roglio, I
Melcangi, R
D'incalci, M
Lauria, G
Ghezzi, P
Cavaletti, G
Bianchi, R
author_sort Cervellini, I
collection OXFORD
description Taxanes, including docetaxel (DOCE), are severely neurotoxic, causing disabling peripheral neuropathy. Co-treatment with neuroprotective agents has been proposed to prevent or reverse this. Besides its hemopoietic effects, erythropoietin (EPO) has neuroprotective and neurotrophic properties and when administered systemically it has a wide range of neuroprotective action in animal models of nervous system damage, including cisplatin-induced peripheral neurotoxicity. The present study investigated the effects of EPO on chemotherapy-induced peripheral neurotoxicity (CINP) by DOCE in vivo and whether it interfered with tumor growth or antitumor activity. Female Fischer rats bearing 13762 mammary carcinoma were randomly divided into four groups: untreated, treated with EPO, DOCE, or DOCE + EPO. DOCE was given once a week (5 mg/kg, i.v.) and EPO three times a week (50 microg/kg i.p.), for 4 weeks. Three other groups of rats without tumors were left untreated or given DOCE or DOCE + EPO. The rats were observed for 4 weeks after treatment. CINP and neuroprotection were evaluated by measuring nociception, electrophysiological, and biochemical parameters. EPO protected against CINP, and tumor growth in EPO-treated rats was the same as in controls. EPO significantly improved the thermal threshold, tail nerve conduction velocity, and intra-epidermal nerve fiber density. These benefits lasted through the follow-up period and EPO speeded-up spontaneous recovery after treatment withdrawal. EPO did not impair DOCE antitumor activity. Since CINP induced by DOCE reproduces the clinical utility of taxane in humans, the findings reported might provide a basis for investigating EPO as a neuroprotective agent in patients receiving therapy with DOCE.
first_indexed 2024-03-07T03:00:07Z
format Journal article
id oxford-uuid:b0af6af4-3a18-4a24-b136-5326d9b96e33
institution University of Oxford
language English
last_indexed 2024-03-07T03:00:07Z
publishDate 2010
record_format dspace
spelling oxford-uuid:b0af6af4-3a18-4a24-b136-5326d9b96e332022-03-27T03:58:14ZThe neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b0af6af4-3a18-4a24-b136-5326d9b96e33EnglishSymplectic Elements at Oxford2010Cervellini, IBello, EFrapolli, RPorretta-Serapiglia, COggioni, NCanta, ALombardi, RCamozzi, FRoglio, IMelcangi, RD'incalci, MLauria, GGhezzi, PCavaletti, GBianchi, RTaxanes, including docetaxel (DOCE), are severely neurotoxic, causing disabling peripheral neuropathy. Co-treatment with neuroprotective agents has been proposed to prevent or reverse this. Besides its hemopoietic effects, erythropoietin (EPO) has neuroprotective and neurotrophic properties and when administered systemically it has a wide range of neuroprotective action in animal models of nervous system damage, including cisplatin-induced peripheral neurotoxicity. The present study investigated the effects of EPO on chemotherapy-induced peripheral neurotoxicity (CINP) by DOCE in vivo and whether it interfered with tumor growth or antitumor activity. Female Fischer rats bearing 13762 mammary carcinoma were randomly divided into four groups: untreated, treated with EPO, DOCE, or DOCE + EPO. DOCE was given once a week (5 mg/kg, i.v.) and EPO three times a week (50 microg/kg i.p.), for 4 weeks. Three other groups of rats without tumors were left untreated or given DOCE or DOCE + EPO. The rats were observed for 4 weeks after treatment. CINP and neuroprotection were evaluated by measuring nociception, electrophysiological, and biochemical parameters. EPO protected against CINP, and tumor growth in EPO-treated rats was the same as in controls. EPO significantly improved the thermal threshold, tail nerve conduction velocity, and intra-epidermal nerve fiber density. These benefits lasted through the follow-up period and EPO speeded-up spontaneous recovery after treatment withdrawal. EPO did not impair DOCE antitumor activity. Since CINP induced by DOCE reproduces the clinical utility of taxane in humans, the findings reported might provide a basis for investigating EPO as a neuroprotective agent in patients receiving therapy with DOCE.
spellingShingle Cervellini, I
Bello, E
Frapolli, R
Porretta-Serapiglia, C
Oggioni, N
Canta, A
Lombardi, R
Camozzi, F
Roglio, I
Melcangi, R
D'incalci, M
Lauria, G
Ghezzi, P
Cavaletti, G
Bianchi, R
The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.
title The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.
title_full The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.
title_fullStr The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.
title_full_unstemmed The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.
title_short The neuroprotective effect of erythropoietin in docetaxel-induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma-bearing rats.
title_sort neuroprotective effect of erythropoietin in docetaxel induced peripheral neuropathy causes no reduction of antitumor activity in 13762 adenocarcinoma bearing rats
work_keys_str_mv AT cervellinii theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT belloe theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT frapollir theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT porrettaserapigliac theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT oggionin theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT cantaa theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT lombardir theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT camozzif theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT roglioi theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT melcangir theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT dincalcim theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT lauriag theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT ghezzip theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT cavalettig theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT bianchir theneuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT cervellinii neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT belloe neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT frapollir neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT porrettaserapigliac neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT oggionin neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT cantaa neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT lombardir neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT camozzif neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT roglioi neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT melcangir neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT dincalcim neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT lauriag neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT ghezzip neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT cavalettig neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats
AT bianchir neuroprotectiveeffectoferythropoietinindocetaxelinducedperipheralneuropathycausesnoreductionofantitumoractivityin13762adenocarcinomabearingrats